CRIS Current Research Information System

FREGA, GIORGIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.680
AS - Asia 3.584
EU - Europa 2.195
AF - Africa 235
Continente sconosciuto - Info sul continente non disponibili 226
SA - Sud America 155
OC - Oceania 3
Totale 10.078
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.594
VN - Vietnam 990
SG - Singapore 977
CN - Cina 863
IT - Italia 598
GB - Regno Unito 315
SE - Svezia 288
DE - Germania 225
HK - Hong Kong 204
IN - India 131
KR - Corea 130
FR - Francia 125
IE - Irlanda 110
CH - Svizzera 104
BR - Brasile 103
NL - Olanda 100
FI - Finlandia 78
RU - Federazione Russa 76
CI - Costa d'Avorio 70
BD - Bangladesh 64
SC - Seychelles 60
CA - Canada 48
JP - Giappone 37
TG - Togo 31
NG - Nigeria 29
PH - Filippine 27
ZA - Sudafrica 26
ID - Indonesia 24
BG - Bulgaria 22
UA - Ucraina 22
AT - Austria 21
JO - Giordania 21
GR - Grecia 20
PL - Polonia 18
EE - Estonia 17
TR - Turchia 17
BE - Belgio 16
AR - Argentina 15
IQ - Iraq 14
MX - Messico 14
TH - Thailandia 13
TW - Taiwan 13
CL - Cile 11
ES - Italia 11
PK - Pakistan 11
PS - Palestinian Territory 10
EC - Ecuador 9
CO - Colombia 8
MY - Malesia 8
IR - Iran 6
NI - Nicaragua 6
SA - Arabia Saudita 6
TN - Tunisia 6
CR - Costa Rica 5
PT - Portogallo 5
RO - Romania 5
DK - Danimarca 4
MA - Marocco 4
HN - Honduras 3
KZ - Kazakistan 3
LT - Lituania 3
PY - Paraguay 3
VE - Venezuela 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
AU - Australia 2
BO - Bolivia 2
EG - Egitto 2
HU - Ungheria 2
IL - Israele 2
JM - Giamaica 2
PA - Panama 2
SI - Slovenia 2
UG - Uganda 2
UZ - Uzbekistan 2
AL - Albania 1
AM - Armenia 1
AO - Angola 1
BH - Bahrain 1
BS - Bahamas 1
CG - Congo 1
CM - Camerun 1
CY - Cipro 1
CZ - Repubblica Ceca 1
DZ - Algeria 1
GE - Georgia 1
GI - Gibilterra 1
GT - Guatemala 1
HR - Croazia 1
HT - Haiti 1
KG - Kirghizistan 1
LB - Libano 1
LK - Sri Lanka 1
MD - Moldavia 1
MT - Malta 1
NO - Norvegia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PE - Perù 1
PR - Porto Rico 1
Totale 9.849
Salva come PNG Salva come JPEG
Città #
Singapore 705
Dallas 411
Ashburn 392
Hefei 287
Chandler 285
Southend 249
San Jose 219
Ho Chi Minh City 205
Hong Kong 194
Dong Ket 188
Fairfield 182
Hanoi 174
Santa Clara 144
Boardman 112
Seoul 112
Dublin 110
Houston 109
Council Bluffs 103
Princeton 97
Beijing 95
Bologna 95
Bern 94
Wilmington 80
Woodbridge 80
Seattle 73
New York 72
Abidjan 70
Helsinki 67
Los Angeles 60
Lauterbourg 58
Rome 58
Cambridge 55
Ann Arbor 53
Frankfurt am Main 42
Milan 38
Berlin 31
Haiphong 31
Lomé 31
Tokyo 30
Nanjing 29
Bengaluru 27
Da Nang 27
Turin 27
Redondo Beach 26
Westminster 25
Redmond 24
Florence 23
Buffalo 22
Sofia 22
São Paulo 22
Amman 21
London 20
Jakarta 19
San Diego 19
Abeokuta 18
Padova 14
Tongling 14
Brussels 13
Ravenna 13
Shanghai 13
Can Tho 12
Jinan 12
Medford 12
Munich 12
Orem 12
Phoenix 12
Toronto 12
Warsaw 12
Chicago 11
Guangzhou 11
Montreal 11
Ninh Bình 10
Denver 9
Hải Dương 9
Mexico City 9
Vienna 9
Wuhan 9
Zhengzhou 9
Chennai 8
Groningen 8
Halhul 8
Istanbul 8
Olalla 8
Saint Petersburg 8
San Francisco 8
Yubileyny 8
Amsterdam 7
Biên Hòa 7
Bremen 7
Lappeenranta 7
Poplar 7
The Dalles 7
Tianjin 7
Torino 7
Atlanta 6
Bari 6
Bến Tre 6
Changsha 6
Forlì 6
Hebei 6
Totale 6.278
Salva come PNG Salva come JPEG
Nome #
Follow-up del cancro del pancreas esocrino 470
Adjuvant treatment in biliary tract cancer 347
D32Left versus right side primary tumor: the correlation with clinical outcome of patients with resected stage II and III colorectal cancer 311
SUSTAINED COMPLETE RESPONSE OF ADVANCED HEPATOCELLULAR CARCINOMA WITH METRONOMIC CAPECITABINE: A REPORT OF THREE CASES 305
An astonishing case of liver-only metastatic colorectal cancer cured by FOLFOXIRI alone 286
Brain Metastases from Biliary Tract Cancer: A Monocentric Retrospective Analysis of 450 Patients 253
Antitumoral efficacy of the protease inhibitor gabexate mesilate in colon cancer cells harbouring KRAS, BRAF and PIK3CA mutations 252
Membrane human equilibrative nucleoside transporter 1 is associated with a high proliferation rate and worse survival in resected intrahepatic cholangiocarcinoma patients not receiving adjuvant treatments 248
Antitumoral Efficacy of Two Turmeric Extracts According to Different Extraction Methods in Hepatocellular Carcinoma Cell Lines 246
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumour Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 231
Membrane localization of human equilibrative nucleoside transporter 1 in tumor cells may predict response to adjuvant gemcitabine in resected cholangiocarcinoma patients 229
INTRAHEPATIC CHOLANGIOCARCINOMA DEVELOPMENT IN A PATIENT WITH A NOVEL BAP1 GERMLINE MUTATION AND LOW EXPOSURE TO ASBESTOS 224
Asbestos exposure as an additional risk factor for small duct intrahepatic cholangiocarcinoma: a pilot study 222
TERC and c-MYC COPY number gain in intraductal papillary mucinous neoplasms (IPMNs): promising biomarkers of progression to malignancy 220
Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: A proof of concept 211
Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience 210
Second-line treatment in advanced biliary tract cancer: Today and tomorrow 210
How to choose between percutaneous transhepatic and endoscopic biliary drainage in malignant obstructive jaundice: An updated systematic review and meta-analysis 204
The (Eternal) Debate on Microwave Ablation Versus Radiofrequency Ablation in BCLC-A Hepatocellular Carcinoma 204
Bone metastases in biliary cancers: A multicenter retrospective survey 203
Anti-EGFR monoclonal antibodies in advanced biliary tract cancer: A systematic review and meta-analysis 199
TERC AND MYC COPY NUMBER GAIN AS POWERFUL GENETIC MARKERS FOR INTRADUCTAL PAPILLARY NEOPLASMS OF THE PANCREAS 198
Bone Turnover Marker (BTM) Changes after Denosumab in Giant Cell Tumors of Bone (GCTB): A Phase II Trial Correlative Study 196
In Reply 196
The role of metronomic capecitabine for treatment of recurrent hepatocellular carcinoma after liver transplantation 188
Intensive follow-up program and oncological outcomes of 278 biliary tract cancer patients after curative intent surgery: A single-center retrospective experience 188
The Potential Role of Adjuvant Chemoradiotherapy in Patients with Microscopically Positive (R1) Surgical Margins after Resection of Cholangiocarcinoma 181
Postsorafenib systemic treatments for hepatocellular carcinoma: Questions and opportunities after the regorafenib trial 180
Challenges in Repurposing Drugs in COVID-19 Pandemic. Debating on Potential New Refinements 179
Plasma membrane localization of human equilibrative nucleoside transporter 1 (hENT-1) to predict better outcome of adjuvant gemcitabine in cholangiocarcinoma (CC) patients. 173
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 171
Chemotherapy in Patients with Advanced Cholangiocarcinoma 168
Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand? 165
Hacking pancreatic cancer: Present and future of personalized medicine 163
The power of kindness: curative treatment with metronomic combination in advanced hepatocellular carcinoma 146
Clinical safety and efficacy of adjuvant chemotherapy in radically resected cholangiocarcinoma patients. 144
Plasma membrane localization of human equilibrative nucleoside transporter 1 (hENT-1) predicts better outcome of adjuvant gemcitabine in cholangiocarcinoma (CC) patients. 131
Experimental HER2- targeted therapies for biliary tract cancer 130
BAP1 in solid tumors 129
Molecular features and targeted therapies in extrahepatic cholangiocarcinoma: Promises and failures 128
NTRK rearranged sarcoma of the bone. Role for larotrectinib in the neoadjuvant setting of an ultra-rare tumor: a case report 126
Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis 124
Histological and imaging features of myoepithelial carcinoma of the bone and soft tissue 123
Microbiota: Overview and implication in immunotherapy-based cancer treatments 114
Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges 113
Nivolumab: an investigational agent for the treatment of biliary tract cancer 103
Case Report: Long lasting response with TKI for combined hepatocellular-cholangiocarcinoma 101
A reduction in tumor volume exceeding 65% predicts a good histological response to neoadjuvant chemotherapy in patients with Ewing sarcoma 101
Hypothesis on the possible relevance of the immunogenic cell death in the treatment of gestational trophoblastic neoplasms 99
The Human Microbiomes in Pancreatic Cancer: Towards Evidence-Based Manipulation Strategies? 93
FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue 89
Hypothyroidism in patients with hepatocellular carcinoma receiving cabozantinib: An unassessed issue 85
The human microbiomes in pancreatic cancer: Towards evidence-based manipulation strategies? 84
Second-line FOLFOX chemotherapy for advanced biliary tract cancer 81
Comparison of histological response across patients with Ewing sarcoma treated with preoperative chemotherapy with or without preoperative radiotherapy 70
Trial Watch: experimental TLR7/TLR8 agonists for oncological indications 52
Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study 36
Hypothyroidism in patients with hepatocellular carcinoma receiving cabozantinib: an unassessed issue 34
A proposed radiological model for preoperative chemotherapy response prediction in patients with skeletal Ewing sarcoma 11
Totale 10.078
Salva come PNG Salva come JPEG
Categoria #
all - tutte 28.761
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.761
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022863 0 29 35 68 61 33 22 54 133 85 198 145
2022/20231.265 122 169 60 133 96 96 36 79 197 47 84 146
2023/2024399 63 55 26 39 22 65 18 29 3 28 31 20
2024/20251.580 92 208 146 109 170 62 93 82 41 117 128 332
2025/20264.276 406 501 653 319 366 200 374 136 706 299 160 156
2026/2027178 79 99 0 0 0 0 0 0 0 0 0 0
Totale 10.078